G
G Pomatico
Researcher at University of Naples Federico II
Publications - 11
Citations - 1741
G Pomatico is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Growth inhibition & Cancer cell. The author has an hindex of 9, co-authored 11 publications receiving 1722 citations.
Papers
More filters
Journal Article
Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor
Fortunato Ciardiello,Rosa Caputo,Roberto Bianco,Damiano,G Pomatico,De Placido S,Ar Bianco,Giampaolo Tortora +7 more
TL;DR: The antitumor effect of this EGFR-selective tyrosine kinase inhibitor ZD-1839 is demonstrated and a rationale for its clinical evaluation in combination with cytotoxic drugs is provided.
Journal Article
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Fortunato Ciardiello,Roberto Bianco,Vincenzo Damiano,G. Fontanini,Rosa Caputo,G Pomatico,S. De Placido,Ar Bianco,John Mendelsohn,Giampaolo Tortora +9 more
TL;DR: A significant potentiation in inhibition of VEGF expression and little or no microvessels were observed in GEO tumors after the combined treatment with the two agents after the antiangiogenic and antitumor activity of monoclonal antibody C225.
Journal ArticleDOI
Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide
Fortunato Ciardiello,Rosa Caputo,Roberto Bianco,Vincenzo Damiano,G Pomatico,Stefano Pepe,A. Raffaele Bianco,Sudhir Agrawal,John Mendelsohn,Giampaolo Tortora +9 more
TL;DR: The combination of anti-EGFR MAb C225 and ited cooperative antiproliferative effects and cooperative antitumor effects on EGFR and PKAI-expressing human renal cancer cell lines are observed.
Journal Article
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
Giampaolo Tortora,Rosa Caputo,G Pomatico,Stefano Pepe,Ar Bianco,Sudhir Agrawal,John Mendelsohn,Fortunato Ciardiello +7 more
TL;DR: HYB 165, a novel DNA/RNA hybrid mixed backbone oligonucleotide that exhibits improved pharmacokinetic and bioavailability properties in vivo and is presently undergoing Phase I trials, is used and provides the basis for a novel strategy of treatment of breast cancer patients.